Spero Therapeutics Inc
NASDAQ:SPRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
US |
|
B
|
Barnes Group Inc
XBER:BG4
|
US |
|
QinetiQ Group PLC
OTC:QNTQF
|
UK |
|
H
|
Hess Corp
F:AHC
|
US |
|
Northam Platinum Holdings Ltd
OTC:NPTLF
|
ZA |
|
ABB India Ltd
BSE:500002
|
IN |
|
United Utilities Group PLC
LSE:UU
|
UK |
|
W
|
Western Digital Corp
F:WDC
|
US |
Spero Therapeutics Inc
Spero Therapeutics is a biotechnology company that develops medicines for hard-to-treat bacterial infections, with a focus on infections caused by drug-resistant Gram-negative bacteria. Its work centers on antibiotic candidates designed to be taken by mouth or given in other convenient ways, so they can treat serious infections that often require hospital care. The company is not a mass drug seller today; it is mainly a research and development business. Its customers are ultimately patients and the doctors and hospitals that treat them, but its money comes from drug development partnerships, licensing deals, grants, and, if its medicines win approval, future product sales or royalty income. What makes Spero’s business model different is that it sits in a narrow part of the pharmaceutical chain: it tries to create new antibiotics where resistance has made older drugs less useful. That means its value depends less on broad consumer demand and more on whether its drug candidates can clear clinical testing, gain regulatory approval, and earn a place in hospital infection treatment.
Spero Therapeutics is a biotechnology company that develops medicines for hard-to-treat bacterial infections, with a focus on infections caused by drug-resistant Gram-negative bacteria. Its work centers on antibiotic candidates designed to be taken by mouth or given in other convenient ways, so they can treat serious infections that often require hospital care.
The company is not a mass drug seller today; it is mainly a research and development business. Its customers are ultimately patients and the doctors and hospitals that treat them, but its money comes from drug development partnerships, licensing deals, grants, and, if its medicines win approval, future product sales or royalty income.
What makes Spero’s business model different is that it sits in a narrow part of the pharmaceutical chain: it tries to create new antibiotics where resistance has made older drugs less useful. That means its value depends less on broad consumer demand and more on whether its drug candidates can clear clinical testing, gain regulatory approval, and earn a place in hospital infection treatment.
Phase III Success: Spero and GSK’s PIVOT-PO Phase III trial for Tebipenem HBr in complicated urinary tract infections met its primary endpoint and was stopped early for efficacy.
FDA Plans: GSK aims to submit the Tebipenem HBr regulatory filing by year-end 2025, with possible FDA action in the second half of 2026.
Financial Position: Spero ended Q2 with $31.2 million in cash and expects its runway, including a recent $23.8 million milestone from GSK, to last into 2028.
Revenue Growth: Q2 revenue rose to $14.2 million, up from $10.2 million a year ago, mainly due to GSK collaboration revenue.
Costs Down: R&D expenses dropped sharply year-over-year, driven by the early PIVOT-PO trial stop.
SPR720 Setback: The Phase IIa study for SPR720 in NTM-PD did not meet its primary endpoint and showed safety concerns.
